Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Switch to Doravirine/Islatravir vs Biktarvy in Virologically Suppressed HIV-1
2022-502079-49-00Phase 3Withdrawn
- Sponsor
- Merck & Co.
- Start
- Apr 2023
- Modality
- Small Molecules
- Countries
- 11
01
Overview
Phase 3, randomised, double-blind trial of doravirine + islatravir in Human immunodeficiency virus infection type 1 (2 arms), sponsored by Merck & Co. Primary endpoints: Percentage of participants with HIV-1 RNA ≥50 copies/mL at Week 48, Percentage of participants who experience adverse events through Week 48 and 1 more. Planned start Apr 2023; status: withdrawn.
02
Drugs
doravirine + islatravir
03
Conditions
Human immunodeficiency virus infection type 1
Beyond the preview
Go deeper on 2022-502079-49-00.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on 2022-502079-49-00.